INVO Fertility Reports Second Quarter 2026 Results Highlighting Revenue Growth and Clinic Platform Profitability
INVO Fertility, Inc. (IVF) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 INVO Fertility Reports Second Quarter 2026 Results Highlighting Revenue Growth and Clinic Platform Profitability Q2 2026 revenue increased 17% as INVO advances organic growth and a disciplined acquisition strategy focused on established, profitable fertility practice
How this was made
The 30-second read
Why it matters
Traders can reassess near-term valuation and risk based on the combination of (1) reported revenue growth, (2) improvement in net income versus prior-year loss, (3) clinic-level profitability, and (4) the Birmingham acquisition structure change to wholly owned.
Market read
Fresh quarterly financials and a corporate ownership change provide a concrete catalyst for repricing IVF’s near-term earnings power and acquisition integration execution.
What to watch
Cash is only $3.7M at June 30, 2026, so investors may focus on funding needs and whether platform investments pressure consolidated results despite clinic-level gains.
Background
SEC 8-K Item 2.02 with Exhibit 99.1 reporting INVO Fertility’s second quarter 2026 financial results and key operational updates.
Ticker impact
INVO Fertility reported Q2 2026 revenue up 17% to $2.18M and clinic-level Adjusted EBITDA of about $333K, plus Birmingham becoming wholly owned.
Near-term bias higher on earnings-quality and profitability improvement, with follow-through dependent on cash burn and sustained clinic-level EBITDA.
The filing provides fresh, quantified quarterly performance (revenue, net income, clinic-level Adjusted EBITDA) and a concrete corporate change (JV converted to wholly owned) that can affect future economics.
Market effects
Adds datapoint that fertility clinic operators can show clinic-level profitability with disciplined acquisitions and organic growth.
No specific regional read-through beyond US clinic footprint.
Limited, company-specific healthcare services update.
Counterpoint
Adjusted EBITDA remains negative at the consolidated level (Adjusted EBITDA of $(1.0)M), so clinic profitability may not yet translate into sustainable corporate earnings.
Key entities
- companyINVO Fertility, Inc.
Nasdaq-listed fertility clinic operator reporting Q2 2026 results and acquisition-related updates in an SEC 8-K.
- businessFamily Beginnings
Indiana-based clinic acquired in February 2026, contributing a full-quarter to Q2 revenue.
- businessBirmingham, Alabama fertility clinic
Converted from joint venture to wholly owned subsidiary in June 2026, increasing future economics participation.
